Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Pharma-Bio Serv's free cash flow for the twelve months ending Jul 31, 2026 was -$421.36K. For fiscal 2025 it was -$221.53K. The highest annual figure on record is $5.41M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$221.53K | – |
| FY2024 | Oct 31, 2024 | -$726.44K | -138.6% |
| FY2023 | Oct 31, 2023 | $1.88M | +228.6% |
| FY2022 | Oct 31, 2022 | $573.19K | -27.8% |
| FY2021 | Oct 31, 2021 | $794.00K | -45.6% |
| FY2020 | Oct 31, 2020 | $1.46M | – |
| FY2019 | Oct 31, 2019 | -$2.27M | -163.0% |
| FY2018 | Oct 31, 2018 | $3.60M | – |
| FY2017 | Oct 31, 2017 | -$979.64K | – |
| FY2016 | Oct 31, 2016 | -$1.10M | -3733.8% |
| FY2015 | Oct 31, 2015 | $30.24K | -99.0% |
| FY2014 | Oct 31, 2014 | $3.12M | -42.2% |
| FY2013 | Oct 31, 2013 | $5.41M | +138.0% |
| FY2012 | Oct 31, 2012 | $2.27M | +12.6% |
| FY2011 | Oct 31, 2011 | $2.02M | +379.1% |
| FY2010 | Oct 31, 2010 | $420.92K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $59.50K | -74.6% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$367.63K | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$392.55K | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $279.32K | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $234.49K | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$305.85K | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$429.49K | -159.2% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$78.59K | -125.4% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$672.24K | -170.3% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$700.74K | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $725.13K | -16.4% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $310.02K | -4.7% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $956.77K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$250.87K | -126.1% |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $867.80K | +99.7% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $325.23K | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$1.10M | -288.5% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | $961.23K | +191.2% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $434.61K | -64.1% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | -$1.19M | – |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $585.62K | -61.1% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $330.04K | – |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $1.21M | – |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -$1.58M | – |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $1.50M | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -$548.94K | -239.8% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -$636.70K | -137.8% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | -$858.68K | -661.5% |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | -$220.80K | -116.2% |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $392.66K | -33.1% |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $1.69M | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | $152.93K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | $1.37M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | $587.24K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$518.95K | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$952.60K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$95.33K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$258.99K | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -$420.47K | – |
See a number that looks wrong?